Biểu đồ giá cổ phiếu MDNAF
MDNAF Thu nhập
Medicenna Therapeutics Corp
$0.3
1.8%
$0
Khi đóng cửa: Jun 22, 16:00:00 GMT-4
$0.3
-1.76%
$0
Phiên sau giờ: Jun 22, 20:00:00 GMT-4
Quay lại
Medicenna Therapeutics Corp (MDNAF) Thu nhập
Thống kê chính
Giá đóng cửa trước
$0.3
Giá mở cửa
$0.2537
Phạm vi ngày
$0.25 - $0.3054
Phạm vi 52 tuần
$0.265 - $1.43
Khối lượng
1.0K
Khối lượng trung bình
75.2K
Tỷ suất cổ tức
--
EPS (TTM)
-0.11
Vốn hóa thị trường
$25.0M
Medicenna Therapeutics Corp. là gì?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
